References
  1. Migliori GB, Wu SJ, Matteelli A, Zenner D, Goletti D, Ahmedov S, Al-Abri S, Allen DM, Balcells ME, Garcia-Basteiro AL, Cambau E. Clinical standards for the diagnosis, treatment and prevention of TB infection. The International Journal of Tuberculosis and Lung Disease. 2022 Mar 1;26(3):190-205.
  2. World Health Organization, Stop TB Initiative (World Health Organization). Treatment of tuberculosis: guidelines. World Health Organization; 2010.
  3. Jeong YJ, Lee KS. Pulmonary tuberculosis: up-to-date imaging and management. AJR Am J Roentgenol. 2008 Sep 1;191(3):834-44.
  4. Kim HY, Cho JG, Akkerman OW, Padanilam X, Seaworth B, Alffenaar JW. Anti-Tuberculosis Drugs and Adverse Events. Essential Tuberculosis. 2021:121-9.
  5. Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Adverse Cutaneous Drug Eruptions. 2012;97:1-7.
  6. García RM, Molina SC. Drug-induced hyperpigmentation: review and case series. The Journal of the American Board of Family Medicine. 2019 Jul 1;32(4):628-38.
  7. Lode H, Rubinstein E. Adverse effects. Quinolone antimicrobial agents. 2003 Aug 12:405-19.
  8. Baggio D, Ananda-Rajah MR. Fluoroquinolone antibiotics and adverse events. Australian prescriber. 2021 Oct;44(5):161.
  9. Lorente M, Ballano A, Juanes A, Pastor MA, Cuevas J. Blue-Gray Pigmentation in Trunk and Extremities in a 71-Year-Old Man.JAMA Dermatol. 2013;149(9):1111–1112.
  10. Redondo RG, Molero VM, Fuentes AM, de Eusebio Murillo E. Le vofloxacin-Induced Hyperpi gmentation.
  11. Connors TM, Restrepo A, Dao Jr H. Brown-gray hyperpigmentation in a photosensitive distribution after levofloxacin exposure. Dermatology Online Journal. 2018;24(7)
  12. Le Cleach L, Chosidow O, Peytavin G, Berry JP, Boisnic S, Le Charpentier Y, Herson S, Frances C. Blue-black pigmentation of the legs associated with pefloxacin therapy. Archives of dermatology. 1995 Jul 1;131(7):856-7.
  13. Llau ME, Viraben R, Montastruc JL. Drug-induced alopecia: review of the literature. Therapie. 1995 Mar 1;50(2):145-50.
  14. World Health Organization. WHO operational handbook on tuberculosis. module 4: Treatment-drug-resistant tuberculosis treatment, 2022 update. World Health Organization; 2022 Dec 15.